Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus vinorelbine for second-line treatment of advanced triple-negative breast cancer
ChiCTR2000035964Phase 2Not yet recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and vinorelbine in breast cancer, sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Objective response rate. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
Rivoceranibvinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000035964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035964.